Imagine a smart balloon that can be placed in a major artery during a heart attack to act like a traffic controller for blood. It stops blood from going to non-essential areas and pushes it toward the brain and heart instead. This gives doctors three times as much time to save the patient compared to standard CPR.
Standard CPR only provides 35% of necessary blood flow, leaving survival rates stagnant at 10% and as low as 3.3% for non-shockable rhythms.
An automated Aortic Balloon Occlusion system featuring a patented sensor-embedded catheter for fluoroscopy-free positioning.
If you are a paramedic service dealing with the fact that CPR only provides 35% of necessary blood flow — this project developed a portable, sensor-embedded catheter that extends the resuscitation window from 20 to 60 minutes.
If you are a device maker dealing with the need for fluoroscopy-free positioning — this project developed a patented sensor system that allows safe catheter placement without X-ray machines.
If you are a hospital dealing with the 3.3% survival rate for non-shockable cardiac arrests — this project developed an automated occlusion system that could increase survival rates by up to 40%.
The device is projected to reach €931.37M in revenues by 2033. It targets a global crisis where cardiac arrest incidence is expected to rise to 11 million cases by 2030.
The project utilizes a patented sensor system for fluoroscopy-free positioning. Based on available project data, the company is pursuing FDA De Novo authorization and global distribution partnerships.
The project has transitioned from porcine models to multi-center human clinical enrollment via the ARISE trial. It has already reached TRL 7 and is moving toward commercial roll-out by 2027.
The project secured a Class III CE mark from TÜV SÜD in Q3 2025 and previously leveraged a 2021 FDA 510(k) clearance.
The commercial roll-out is projected for 2027, following the completion of the ARISE trial and regulatory authorizations.
The project is led by a single SME, NEURESCUE APS, representing a 100% industry ratio. This lean structure suggests a highly focused commercial drive, utilizing EU funding to bridge the gap between a TRL 7 prototype and a full commercial launch.
Contact NEURESCUE APS in Denmark for partnership opportunities.
Contact us to explore licensing opportunities for the patented sensor system.
